Cogstate Posts Strong FY 2026 Growth
Cogstate Limited said full-year revenue rose 15% in FY 2026, driven by growth across revenue, contracts, and trial activity. The company’s clinical trials business drove much of the improvement, helped by stronger demand in mood, sleep, and other neurological conditions, as well as continued strength in Alzheimer’s disease research.
Revenue Miss Weighs on Shares
However, the company’s latest reported revenue came in far below Wall Street expectations, helping keep its shares under pressure. The stock was last at $2.74, down 1.79% from the previous close of $2.79, after the company reported revenue of $21.85 million versus a forecast of $43.51 million, a shortfall of 49.78%.
Stronger Full-Year Operating Trends
Despite the revenue miss, the broader operating picture was stronger than the headline revenue comparison suggests. The company said FY 2026 was a strong year for contract wins and trial growth, with sales contracts rising sharply, and contracted future revenue also increasing. This suggests the revenue miss may reflect timing rather than a collapse in demand.
Management’s Outlook
Management said FY 2027 revenue recognition from contracted work is expected to be AUD 48.3 million, up 54% from the prior year baseline. The company also expects EBITDA margin to hold around 30% in FY 2027, despite increased technology spending. Gross margin is targeted at 58% to 60%, with potential for improvement beyond that range as automation reduces manual work.
Strategic Focus on AI Automation
The company also said it will keep its share buyback program open and will continue to use capital carefully. A major strategic focus is a two-year AI operations automation program covering FY 2027 and FY 2028, which includes workflow automation, portal development, and more technology releases over time.
Analysts Weigh In
Analysts focused on the company’s AI spending, contract conversion, and growth in channel partnerships. One key question centered on how much technology spending is planned and what return it could deliver. Management said the program is based on detailed process mapping and is aimed at automating manual workflows and improving visibility for customers and trial sites.
Conclusion
Cogstate’s strong full-year growth and improving profitability are encouraging signs, but the revenue miss weighs on shares. The company’s strategic focus on AI automation and its robust financial foundation suggest that it has a solid foundation for future growth and margin expansion.